Articles by Amy Swinderman

LIVE May 20th, 2021 at 2:30 PM ET
In this webinar, Berkeley Lights scientists present a new platform for antibody discovery and cell line development that accelerates the identification and production of leading therapeutic molecules.

University, Belgian company to expand healthcare applications for silicon nanotechnology

Researchers at UCLA School of Dentistry envision creation of simple saliva test to detect pancreatic cancer

Roche bolsters biologics production while quietly closing 454 Life Sciences

New leadership, NextBio acquisition will usher in company’s focus on building an enterprise informatics solutions business

A group of researchers led by the Cell Biology and Stem Cell Sciences division of Life Technologies has discovered a new way to grow neural stem cells with the hope that they may be used to accelerate drug discovery and development for brain injuries and disease.

MSKCC, Rockefeller University and Weill Cornell to conduct early-stage drug discovery with pharma

Already facing tough decisions caused by the sequestration, the U.S. government shutdown further stymies American biomedical researchers

2,832 pages: How do you measure, measure five years? This editorial column will be my last in Drug Discovery News, as in a few short weeks, I will be stepping down from my post as chief editor of the news organization and entering a new chapter in my life. As I clean up my office and prepare to pass the baton to Jeff Bouley, who will be your new chief editor in 2014, I am reflecting with great fondness some of the amazing people I have met and the remarkable experiences I have had in the past five and a half years of leading our editorial team in the creation of these pages. Thus, as I exit stage left, I will take inspiration from the song “Seasons of Love” from the hit musical “Rent” (which explains my headline and lead, if you’re not familiar with it) and recall some of the memorable ways in which I will measure my tenure.

High court declines to hear case questioning whether punitive damages should be awarded in product liability lawsuits

A study out of UC Davis has honed in on a potential biomarker for certain types of attention-deficit/hyperactivity disorder, a finding that may help distinguish between different subtypes of the disorder

Seeking to stave off generic competition, Amgen spends $10.4 billion to acquire Onyx and its FDA-approved cancer drug, Kyprolis

When we went to press with this issue, close to 1 million government workers were furloughed, some members of Congress gave up their salary pay and government agencies key to the welfare of the drugmaking industry went on a hiatus of undetermined length. The NIH in particular was already smacked down by the sequestration earlier this year, losing $1.5 billion out of its already stretched-thin operating budget. Now the bruised-up agency stands to lose an estimated $600 million more when the government reopens.

One of the aspects of drug discovery that holds tremendous promise for creating better activity profiles--molecular modeling--received a leg up recently when scientists from the Florida campus of The Scripps Research Institute (TSRI) published a paper describing improvements they have made to the methods involved in generating computer models of molecules